Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine
Oncotarget · 19.08.2026 · 17 (1) · 381-387
DOI: 10.18632/oncotarget.28912 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncotarget, erschienen am 19.08.2026. Verfasst von Kelly Crane und 9 weiteren Autor:innen. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Mutation, Urogenital Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
Crane, K., Bhat, K. R. S., Grivas, P., Necchi, A., Bratslavsky, G., Shapiro, O., Jacob, J. M., Goldberg, H., Sager, R., & Ross, J. S. (2026). Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine. Oncotarget, 17(1), 381-387. https://doi.org/10.18632/oncotarget.28912
Vancouver
Crane K, Bhat KRS, Grivas P, Necchi A, Bratslavsky G, Shapiro O, et al. Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine. Oncotarget. 2026;17(1):381-387. doi:10.18632/oncotarget.28912
BibTeX
@article{Crane2026,
author = {Crane, Kelly and Bhat, K R Seetharam and Grivas, P and Necchi, Andrea and Bratslavsky, Gennady and Shapiro, Oleg and Jacob, Joseph M and Goldberg, Hanan and Sager, Rebecca and Ross, Jeffery S},
title = {Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine},
journal = {Oncotarget},
year = {2026},
volume = {17},
number = {1},
pages = {381--387},
doi = {10.18632/oncotarget.28912}
}
EUVIMED